Tauriga Sciences, Inc. And Breathe ECig Corp. Enter License Agreement To Co-Develop and Co-Commercialize New CBD E-Cigarette

LOS ANGELES  and KNOXVILLE, Tenn., March 16, 2015 /PRNewswire/ — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga”), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, and Breathe eCig Corp. (BVAP) (“Breathe”), a socially responsible e-cigarette company, announced today that the two companies have entered into a license agreement to co-develop and co-commercialize a new cannabidiol (CBD) e-cigarette.  This new product will utilize Breathe’s patent pending, proprietary device that dispenses a measured and consistent amount of active ingredient per puff and that also features an optional childproofing device.  Tauriga will be responsible for the active ingredient and will source and qualify the CBD oil and will formulate the contents of the pre-filled cartridges and refill units.  Tauriga and Breathe will share the net profits equally from the CBD e-cigarette product line.

Tauriga Chairman and CEO Dr. Stella M. Sung states, “This agreement represents a true partnership for developing an exciting product line that reflects our shared vision of cannabis as an important and rich source for natural and complementary medicine.”

CBD has been associated with many medicinal properties and therapeutic benefits, yet unlike THC, it does not create a psychoactive “high.”  Preclinical studies using animal models suggest that CBD has anticonvulsant, anxiolytic/anti-depressant, anti-inflammatory, antiemetic, and anti-oxidant properties.  As such, CBD may have important therapeutic benefits in the treatment of a wide range of conditions, including chronic pain, neurodegenerative diseases, anxiety, nausea, cancer, arthritis, and other health concerns.

Breathe’s founder and CEO Josh Kimmel commented, “The CBD e-cigarette product line that we are co-developing with Tauriga is an ideal application of our technology and is absolutely consistent with our goal of reducing secondhand smoke and other dangers associated with conventional combustible cigarettes.  We also have the ability to quickly expand our CBD e-cigarette product line by incorporating Breathe’s organic and natural flavors and advanced vapors developed in an FDA-certified factory.”

Both Tauriga and Breathe believe there is a large and dynamic market for CBD e-cigarettes, and the companies’ new product line will combine attractive and sought after components in two rapidly growing sectors, e-cigarettes and natural wellness.   According to  a March, 2014 equity research report from Wells Fargo Securities, LLC,  the current US retail e-vapor market is an estimated $2.2 billion, and much of the near term growth will be driven by the vapors and tanks (the natural wellness content), even more so than by the devices.

Tauriga’s recently launched natural wellness product line currently consists of six products.  Two of these products contain cannabidiol (CBD) oil extracted from non-GMO industrial hemp as their key ingredient: CannaCaviar, the Company’s cannabidiol (CBD) soft gels; and TopiCanna, Tauriga’s proprietary topical medicinal cannabis cream.  Both TopiCanna and CannaCaviar are designed to provide potential natural wellness and healing properties without psychoactive effects.  In addition to CannaCaviar and TopiCanna, Tauriga has a non-cannabis containing line of natural wellness dietary supplements.  These natural supplements include IndiCalm, natural calming formula without inducing cognitive impairment; ClearNaze, a natural decongestant without stimulant or drowsiness effects; Satietiva, an amino acid-based appetite suppressant; and MendWCan, a highly pure, potent and palatable Omega 3 supplement.  For more information on Tauriga’s natural wellness product line, please visit www.taurigastore.com.

About Tauriga Sciences, Inc.:

Tauriga Sciences, Inc. (TAUG) is a diversified life sciences company focused on generating profitable revenues in the natural wellness sector and in developing a proprietary synthetic biology platform technology.  The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets that is capital efficient and of significant value to the shareholders. The Company’s business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. Please visit the Company’s corporate website at www.tauriga.com and the Company’s e-commerce website at www.taurigastore.com.

About Breathe:

Breathe was founded in 2012 as a research and development company in Knoxville, Tennessee with the mission to develop a better e-cigarette than was available on the market. Now holding multiple patents (pending) for its groundbreaking product, BVAP, Breathe is not your typical e-cig manufacturer. With a commitment to remaining socially responsible through innovative product development, consumer outreach and education, Breathe challenges the e-cig industry establishment. To find out more, visitwww.breathecig.com.

 

NON SOLICITATION:

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted. Any securities offered or issued in connection with the above-referenced merger and/or investment have not been registered, and will be offered pursuant to an exemption from registration.

 

DISCLAIMER:

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG’s and BVAP’s predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission. This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

Food and Drug Administration Disclaimer:  None of the statements contained in this press release regarding any of the products either offered or to be offered in the future by the Company have been evaluated by the Food and Drug Administration.  Additionally, none of the products is intended to diagnose, treat, cure, or prevent any disease.

 

CONTACT:

Dr. Stella M. Sung,

Chairman and Chief Executive Officer

Tauriga Sciences, Inc.

www.tauriga.com

San Diego: + 1-858-353-5749

Montreal: +1-514-840-3697

Email: ssung@tauriga.com

Joshua Kimmel

CEO

Breathe eCigs

www.BreatheCig.com

+1 800 905 4014

+1 865 281 1330

email: Josh@Breathecig.com

MEDIA CONTACT: 

Heather Ripley

Ripley PR

+1-865-977-1973

hripley@ripleypr.com

No Comments

Sorry, the comment form is closed at this time.